Marc Singer
Managing Partner @ OUP (Osage University Partners)
Bala Cynwyd, United States
Marc Singer is a Series A investor at OUP (Osage University Partners) in Bala Cynwyd focused on Biotechnology and Medical. Marc Singer joined Osage in 2008 to help develop and launch Osage University Partners. He is an eighteen year veteran of the venture capital industry. Marc was previously a General Partner of BEV Capital, an early stage venture capital firm he co-founded in 1997. Marc helped BEV raise and invest over $200M in over 40 companies and co-investedwith over 100 other venture capital firms. Marc managed or co-managed eighteen of BEV’s investments, served as an active board member and/or Chairman for the majority of his investments, and successfully managed multiple companies from start-up through IPO or trade sale. Prior to co-founding BEV in 1997, Marc worked at Consumer Venture Partners, another venture capital firm which he joined in 1993. Marc earned his BS from The Wharton School of the University of Pennsylvania.Marc resides in Penn Valley, PA with his wife Leah and three children.
- Total investments:
- 27
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries Marc Singer invests in
Stages Marc Singer invests in
Countries Marc Singer invests in
Investment Focus
Industry
- Biotechnology 4 (15%)
- Medical 3 (11%)
- Software 3 (11%)
- Hardware 2 (7%)
- Electronics 2 (7%)
Stage
- Series A 6 (22%)
- Series C 6 (22%)
- Series B 5 (19%)
- Series D 4 (15%)
- Funding Round 4 (15%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Menlo Security
|
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails.Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, NeubergerBerman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California. | $100M / Series E / Nov 12, 2020 | |
StreetLight Data
|
StreetLight Data brings mobility patterns to light for planners, modelers, and engineers by giving them on-demand access to the Big Data resources and processing software for transportation. Their online platform, StreetLight InSight lets its users turn anonymous location data from millions of mobile devices into customized, actionable analytics.It was founded in 2012 and is headquartered in San Francisco, California. | $15M / Series D / Jun 11, 2020 | |
Cleave Therapeutics
|
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer. | $12M / Series C / Aug 06, 2019 | |
|
Menlo Security
|
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails.Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, NeubergerBerman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California. | $75M / Series D / Jul 09, 2019 | |
MC10
|
MC10, Inc. extends human capabilities through virtually invisible and conformal electronics. They reshape rigid, conventional electronics into thin, flexible devices that can stretch, bend and twist seamlessly with their bodies and the natural world. It combines breakthrough technology with innovative engineering to develop products that advancethe quality of life. The company's end-to-end system designed for In-Home and In-Clinic Study Execution. Its proprietary BioStamp system wearable health tech creates comfortable, discreet sensors that can be applied anywhere on the body for targeted data collection. With location-specific sensing capabilities, BioStamp sensors are able to retrieve real-world data about muscle activation and movement. | $10M / Aug 20, 2018 | |
|
StreetLight Data
|
StreetLight Data brings mobility patterns to light for planners, modelers, and engineers by giving them on-demand access to the Big Data resources and processing software for transportation. Their online platform, StreetLight InSight lets its users turn anonymous location data from millions of mobile devices into customized, actionable analytics.It was founded in 2012 and is headquartered in San Francisco, California. | $10M / Series C / Jul 17, 2018 | |
Clinipace
|
Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina. | $19.9M / Mar 28, 2018 | |
|
Menlo Security
|
Menlo Security provides a cloud-based isolation platform that protects organizations from cyberattacks by eliminating the threat of malware from websites, documents, and emails.Menlo Security is trusted by major global businesses, including Fortune 500 companies and financial services institutions, and backed by Vista Equity Partners, NeubergerBerman, General Catalyst, Sutter Hill Ventures, Engineering Capital, Osage University Partners, American Express Ventures, Ericsson Ventures, HSBC, and JP Morgan Chase. Menlo Security was founded in 2012 and headquartered in Mountain View, California. | $40.3M / Series C / Dec 11, 2017 | |
Everactive
|
Everactive's custom ultra-low-power chips enable completely battery-less wireless sensors that form the foundation of end-to-end IoT data services. The company technology allows for low cost, long-lived, and intelligent instrumentation of industrial operations. Its end-to-end solutions are built upon innovative advances in ultra-low-powercircuit design and wireless communication that enable the company to power its Eversensors exclusively from harvested energy. The company also creates networking and cloud software to provide a service focused on providing customers with valuable insights from generated and self-sustaining data streams.The company was founded on 2012 and is based in Santa Clara, California. | $40.3M / Oct 17, 2017 | |
|
Cleave Therapeutics
|
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer. | $37M / Series B / Aug 17, 2016 | |
| See all 27 investments → | |||
Co-Investors
About OUP (Osage University Partners)
Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at allstages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.
OUP (Osage University Partners) Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna Turetsky
General Partner of PxB Fund
|
|||
Beth Grafstrom
Vice President of Finance
|
|||
Kirsten Leute
Partner, University Relations
|
|||
Louis Berneman
Founding Partner
|
|||
|
Marc Singer
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Marc Singer invest in?
Marc Singer invests primarily in Biotechnology, Medical and Software startups, most often at Series A and Series C stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Marc Singer last invest?
The most recent investment recorded for Marc Singer closed in Nov 2020. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
